Nabriva Therapeutics (NBRV) Stock Analysis

What Nabriva Therapeutics does

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

Key metrics

ETFs linked to NBRV

Broad-market and Healthcare sector ETFs an investor holding Nabriva Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NBRV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Nabriva Therapeutics?

Nabriva Therapeutics trades under the ticker NBRV on NASDAQ.

Which exchange is NBRV listed on?

NBRV is listed on NASDAQ.

What sector does Nabriva Therapeutics operate in?

Nabriva Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NBRV in a portfolio?

PortView shows NBRV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.